Discounted Cash Flow Rating

Strong Buy

Return on Equity Rating

Strong Buy

Debt to Equity Rating

Neutral

Price to Earnings Rating

Neutral

Analyst Rating

Buy

Simple Moving Average

Sell

Exponential Moving Average

Sell

Relative Strength Index

Buy

Standard Deviation

Buy

Williams %R

Strong Buy

Average Directional Index

Sell

Insider Trading

Strong Buy

Wall Street Data Solutions Rating

Buy

A

First Wave BioPharma, Inc. Common Stock (FWBI)

Pharmaceutical Preparations

https://www.firstwavebio.com

First Wave BioPharma Inc is a clinical-stage biopharmaceutical company specializing in the development of targeted, non-systemic therapies for gastrointestinal diseases. It is advancing a therapeutic development pipeline populated with multiple clinical-stage programs built around its two proprietary technologies-niclosamide, an oral small molecule with anti-viral and anti-inflammatory properties, and the biologic adrulipase, a recombinant lipase enzyme designed to enable the digestion of fats and other nutrients.

777 YAMATO ROAD, SUITE 502
BOCA RATON, FL

Current Price

---.--

% Change Today

0.00%

Change Amt. Today

0.00

Active Status

Active

Listing Date

10/11/2016

Market Cap

5,994,592

Shares Outstanding

680,000

Weighted SO

674,998

Total Employees

N/A

Upcoming Earnings

08/12/2024

Similar Tickers

QNRX --.--%

BWV --.--%

PXMD --.--%

REVB --.--%

HILS --.--%

DRMA --.--%

PBLA --.--%

CFRX --.--%

ICU --.--%

Beta

1.2810

Last Div

0.0000

Range

2.3335-59.998

Chg

0.1300

Avg Vol

72481

Mkt Cap

5994592

Exch

NASDAQ

Country

US

Phone

561 589 7020

DCF Diff

-5.6174

DCF

8.5774

Div Yield

0.0000

P/S

43.1987

EV Multiple

-0.4567

P/FV

0.0670

Div Yield %

0.0000

P/E

-0.8471

PEG

-0.0094

Payout

0.0000

Current Ratio

1.2133

Quick Ratio

0.5559

Cash Ratio

0.5559

DSO

0.0000

DIO

0.0000

Op Cycle

0.0000

DPO

11016.3180

CCC

-11016.3180

Gross Margin

0.5233

Op Margin

-150.8565

Pretax Margin

-151.4514

Net Margin

-44.3670

Eff Tax Rate

0.7069

ROA

-0.0676

ROE

-0.2876

ROCE

-0.2464

NI/EBT

0.2929

EBT/EBIT

1.0039

EBIT/Rev

-150.8565

Debt Ratio

0.0752

D/E

0.0880

LT Debt/Cap

0.0759

Total Debt/Cap

0.0809

Int Coverage

-262.7331

CF/Debt

-1.9369

Equity Multi

1.1704

Rec Turnover

0.0000

Pay Turnover

0.0331

Inv Turnover

0.0000

FA Turnover

0.6698

Asset Turnover

0.0015

OCF/Share

-7.5367

FCF/Share

-7.8204

Cash/Share

1.9478

OCF/Sales

-95.6937

FCF/OCF

1.0377

CF Coverage

-1.9369

ST Coverage

-28.9949

CapEx Coverage

-26.5585

Div&CapEx Cov

-26.5585

P/BV

0.0670

P/B

0.0670

P/S

43.1987

P/E

-0.8471

P/FCF

-0.4350

P/OCF

-0.3927

P/CF

-0.3927

PEG

-0.0094

P/S

43.1987

EV Multiple

-0.4567

P/FV

0.0670

DPS

0.0000

Latest Headlines (EST)

GlobeNewswire Inc. Dec 27, 11:55 First Wave BioPharma Announces Exercise of Warrants and Issuance of New Warrants in a Private Placement for $4.8 Million Gross Proceeds Priced GlobeNewswire Inc. Dec 27, 11:55 First Wave BioPharma Announces Exercise of Warrants and Issuance of New Warrants in a Private Placement for $4.8 Million Gross Proceeds Priced GlobeNewswire Inc. Dec 27, 06:00 First Wave BioPharma Announces Streamlining of Clinical Pipeline with Non-Binding Term Sheet to Sell Niclosamide IBD Program GlobeNewswire Inc. Dec 18, 06:00 First Wave BioPharma Announces Entry into Term Sheet for Business Combination with ImmunogenX Establishing a Leading Late-Stage GI-Focused Biopharmaceutical Company GlobeNewswire Inc. Dec 14, 09:15 First Wave BioPharma Announces 1-for-20 Reverse Stock Split and Results of the Special Meeting of Stockholders

Revenue Product Segmentation